The S&P 500 is an index that tracks 500 of the largest companies listed on US stock exchanges. It’s widely regarded as one of the best trackers of shares to buy in the US, delivering a compound annual return of 10.2% since 1957.
Since January 2019, investors in the S&P 500 have enjoyed gains of 84%. But despite these impressive results, several UK stocks have outperformed the S&P 500 in the past five years.
I’m looking at three impressive stocks that make me proud to be British.
BAE Systems
The largest defence contractor in Europe, BAE Systems (LSE:BA.) is a UK-based company with consistently impressive results. Now at £11.66 per share, it’s up 135% since early 2019. The share price shot up in early 2022 when the Ukraine conflict prompted demand for increased defence spending in Europe. Following the escalation of geopolitical tensions in the Middle East towards the end of 2023, the price increased even more.
But such rapid growth comes at a cost. With such a high share price, there’s little room left to grow. Analysts predict a lacklustre 3.3% earnings growth rate for BAE and, with a dividend yield of only 2.4%, it leaves little to be desired. I still think it’s a great stock that would make a solid addition to my portfolio, I just wish I had bought in earlier.
AstraZeneca
AstraZeneca (LSE:AZN) is also a defence company of sorts, albeit for the human body. The Anglo-Swedish pharmaceutical firm became a household name during the pandemic due to its COVID-19 vaccine. Recently, it announced a $1.2bn deal to acquire NASDAQ-listed Gracell Biotechnologies, a Chinese biopharmaceutical company dealing in cancer and autoimmune disease treatments. Unlike AstraZeneca, Gracell has struggled to turn a profit, with its shares down 60% since listing.
AstraZeneca’s share price is up 89% in the past five years, yet analysts still estimate it’s trading 45% below fair value. Earnings grew 189% in the past year alone and are forecast to grow a further 17.3% per year. Numbers like that are hard to ignore – so what’s the catch?
Debt, of course.
An eye-watering £22.3bn worth.
Although it has more than sufficient equity to cover it, AstraZeneca’s short-term assets fall short of both its short-term and long-term liabilities. I wouldn’t say it’s a huge concern, but something I’d keep an eye on if I were a shareholder.
London Stock Exchange Group
The London Stock Exchange Group (LSE:LSEG) is another company I wish I’d clocked onto earlier. The shares are up 111% in the past five years, and almost 10 times higher than they were 10 years ago. More than just the company that runs the London Stock Exchange, the London Stock Exchange Group has a range of subsidiaries, including the Italian Stock Exchange, Refinitiv, FTSE Group, and FTSE Russell.
While the London Stock Exchange Group did a great job outperforming the S&P 500 over the past five years, recent results are less impressive. Profit margins are down to 8.2% compared to last year’s 11.9% and its future return on equity (ROE) is only 8.8%. Coupled with a dividend yield of only 1.2%, these stats don’t convince me to dive into the shares right now – but they’re on my radar.
The post They outperformed the S&P 500 over 5 years! Are these the best UK shares to buy now? appeared first on The Motley Fool UK.
Should you buy AstraZeneca now?
Don’t make any big decisions yet.
Because Mark Rogers — The Motley Fool UK’s Director of Investing — has revealed 5 Shares for the Future of Energy.
And he believes they could bring spectacular returns over the next decade.
Since the war in Ukraine, nations everywhere are scrambling for energy independence, he says. Meanwhile, they’re hellbent on achieving net zero emissions. No guarantees, but history shows…
When such enormous changes hit a big industry, informed investors can potentially get rich.
So, with his new report, Mark’s aiming to put more investors in this enviable position.
Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!
Grab your FREE Energy recommendation now
setButtonColorDefaults(“#5FA85D”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43A24A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#FFFFFF”, ‘color’, ‘#FFFFFF’);
})()
More reading
Here’s why the BAE share price rose 30% in 2023
If I’d put £5k in BAE Systems shares at the start of 2022, here’s what I’d have now
2 fantastic growth stocks investors should consider buying!
I’m buying FTSE 100 star BAE Systems as it pulls off deals worth billions
Best British dividend stocks to consider buying in January
Mark Hartley has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca Plc and BAE Systems. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
